Mycobacterial resistance is a rapidly increasing phenomenon requiring the identification of new drugs effective against multidrug-resistant pathogens. The inhibition of protein tyrosine phosphatase B (MptpB), which interferes with host immune responses, may provide a new strategy to fight tuberculosis (TB), while preventing cross-resistance issues. On this basis, starting from a virtual screening (VS) campaign and subsequent structure elucidation studies guided by X-ray analyses, an unexpected γ-lactone derivative (compound 1) with a significant enzymatic activity against MptpB was identified. The structural characterization of compound 1 was described by means of NMR spectroscopy, HRMS, single crystal X-ray diffraction and Hirshfeld surface analysis, allowing a detailed conformational investigation. Notably, the HPLC separation of (±)-1 led to the isolation of the most active isomer, which emerged as a very promising MptpB inhibitor, with an IC50 value of 31.1 μM. Overall, the new chemotype described herein might serve as a basis for the development of novel treatments against TB infections.

Virtual screening and crystallographic studies reveal an unexpected γ-lactone derivative active against MptpB as a potential antitubercular agent / G. Cazzaniga, M. Mori, F. Meneghetti, L.R. Chiarelli, G. Stelitano, I. Caligiuri, F. Rizzolio, S. Ciceri, G. Poli, D. Staver, G. Ortore, T. Tuccinardi, S. Villa. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - 234:(2022 Apr 15), pp. 114235.1-114235.13. [10.1016/j.ejmech.2022.114235]

Virtual screening and crystallographic studies reveal an unexpected γ-lactone derivative active against MptpB as a potential antitubercular agent

G. Cazzaniga
Primo
;
M. Mori
Secondo
;
F. Meneghetti;S. Ciceri;S. Villa
Ultimo
2022

Abstract

Mycobacterial resistance is a rapidly increasing phenomenon requiring the identification of new drugs effective against multidrug-resistant pathogens. The inhibition of protein tyrosine phosphatase B (MptpB), which interferes with host immune responses, may provide a new strategy to fight tuberculosis (TB), while preventing cross-resistance issues. On this basis, starting from a virtual screening (VS) campaign and subsequent structure elucidation studies guided by X-ray analyses, an unexpected γ-lactone derivative (compound 1) with a significant enzymatic activity against MptpB was identified. The structural characterization of compound 1 was described by means of NMR spectroscopy, HRMS, single crystal X-ray diffraction and Hirshfeld surface analysis, allowing a detailed conformational investigation. Notably, the HPLC separation of (±)-1 led to the isolation of the most active isomer, which emerged as a very promising MptpB inhibitor, with an IC50 value of 31.1 μM. Overall, the new chemotype described herein might serve as a basis for the development of novel treatments against TB infections.
No
English
Mycobacterium tuberculosis; LMW-Phosphatases; Immune escape mechanisms; Tuberculosis; Molecular modeling; SC-XRD;
Settore CHIM/08 - Chimica Farmaceutica
Articolo
Esperti anonimi
Ricerca di base
Pubblicazione scientifica
15-apr-2022
5-mar-2022
Elsevier
234
114235
1
13
13
Pubblicato
Periodico con rilevanza internazionale
crossref
Aderisco
info:eu-repo/semantics/article
Virtual screening and crystallographic studies reveal an unexpected γ-lactone derivative active against MptpB as a potential antitubercular agent / G. Cazzaniga, M. Mori, F. Meneghetti, L.R. Chiarelli, G. Stelitano, I. Caligiuri, F. Rizzolio, S. Ciceri, G. Poli, D. Staver, G. Ortore, T. Tuccinardi, S. Villa. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - 234:(2022 Apr 15), pp. 114235.1-114235.13. [10.1016/j.ejmech.2022.114235]
partially_open
Prodotti della ricerca::01 - Articolo su periodico
13
262
Article (author)
si
G. Cazzaniga, M. Mori, F. Meneghetti, L.R. Chiarelli, G. Stelitano, I. Caligiuri, F. Rizzolio, S. Ciceri, G. Poli, D. Staver, G. Ortore, T. Tuccinardi...espandi
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0223523422001374-main.pdf

Open Access dal 06/03/2024

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 2.31 MB
Formato Adobe PDF
2.31 MB Adobe PDF Visualizza/Apri
1-s2.0-S0223523422001374-main(1).pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 2.22 MB
Formato Adobe PDF
2.22 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Villa et al. EJMC 2022.pdf

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 1.1 MB
Formato Adobe PDF
1.1 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/915811
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 15
  • OpenAlex ND
social impact